ROTOP and IRE ELiT Form Distribution Partnership for the Ga-68 Generator GalliAd in Germany
Dresden (Germany), Fleurus (Belgium) – January 7, 2021 – ROTOP Pharmaka and IRE ELiT announce that they have entered into an exclusive distribution agreement for GalliAd, the 68Ge/68Ga generator from IRE ELiT, in Germany.
This strategic move represents an important step toward ensuring nationwide access to GalliAd generators in Germany. Existing GalliAd customers will continue to receive full support from ROTOP Pharmaka and will be informed about the details in the coming days.
Jens Junker, Managing Director of ROTOP Pharmaka, looks to the future with optimism: “We are proud to enter into a partnership with IRE ELiT, one of Europe’s leading radiopharmaceutical companies, driving innovation for the benefit of patients and nuclear medicine. With the GalliAd generator, ROTOP expands its radiopharmaceutical portfolio in Germany and continues its strategy of offering a broad range of radiopharmaceutical products.”
“This partnership will strengthen our position in the European market and contribute to the global development of this important radiopharmaceutical,” says Erich Kollegger, CEO of IRE ELiT. “Combining our expertise with ROTOP’s distribution strength will benefit both patients and nuclear medicine specialists.”
Ähnliche Beiträge
New CFO at ROTOP – Dr. Michael Peterseim
March 13, 2026 - We’re pleased to Welcome Dr. Michael Peterseim as our new Chief Financial Officer (CFO) at ROTOP. Dr. Peterseim brings many years of experience in financial leadership and has successfully guided companies through transformation processes, strengthened performance, and executed strategic transactions, particularly in growth situations.
ROTOP Pharmaka Welcomes State Minister Dirk Panter: Radiopharmacy as a Key Technology in Modern Cancer Care
January 9, 2026 - ROTOP Pharmaka welcomed Saxony’s State Minister Dirk Panter during the region’s Radiopharmacy Theme Day. The exchange highlighted the importance of modern radiopharmacy for cancer care as well as ROTOP’s contribution through diagnostics, ready to use patient doses, and CDMO services, with a particular focus on theranostic concepts.
ROTOP featured in VentureCapital Magazine
August 15, 2025 - We are delighted to be featured in the latest issue of VentureCapital Magazine, which spotlights the Dresden region as a high-performance hub for key players and innovators in radiopharmaceutical innovation. ROTOP Pharmaka is recognized as a leading manufacturer of radiopharmaceuticals, including an iodine-123 compound used in Parkinson’s diagnostics. The article also emphasizes the strong network we are part of – combining research collaborations, advanced manufacturing, and the development of innovative theranostic solutions.
